
RealRate

PHARMACEUTICAL 2021

MADRIGAL PHARMACEUTICALS INC.



Rank 377 of 409



RealRate

PHARMACEUTICAL 2021

MADRIGAL PHARMACEUTICALS INC.



Rank 377 of 409

The relative strengths and weaknesses of MADRIGAL PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MADRIGAL PHARMACEUTICALS INC. compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 164% points. The greatest weakness of MADRIGAL PHARMACEUTICALS INC. is the variable Net Income, reducing the Economic Capital Ratio by 488% points.

The company's Economic Capital Ratio, given in the ranking table, is -783%, being 428% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	285,163
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	46,557
Liabilities, Non-Current	468
Other Assets	785
Other Compr. Net Income	-169
Other Expenses	184,809
Other Liabilities	0
Other Net Income	4,329
Property and Equipment	1,047
Research and Development	184,809
Revenues	100
Selling, General and Administrative Expense	21,864

Output Variable	Value in 1000 USD
Assets	286,995
Liabilities	47,025
Expenses	391,482
Stockholders Equity	239,970
Net Income	-387,053
Comprehensive Net Income	-387,138
Economic Capital Ratio	-783%